CJC-1295 and ipamorelin are not alternatives — they act on different receptor systems. Understanding why they are studied together requires understanding what each does alone.
Research reference only. Not medical advice or dosing guidance.
| Dimension | CJC-1295 | Ipamorelin |
|---|---|---|
| Receptor | GHRH receptor (GHRHR) | Ghrelin receptor (GHS-R1a) |
| Pathway | cAMP / PKA cascade in somatotrophs | IP₃ / Ca²⁺ cascade in somatotrophs |
| Natural ligand | GHRH (hypothalamic pulse) | Ghrelin (gut-derived, pulsatile) |
| Chain length | 30 AA (no DAC) / 30 AA + DAC | 5 AA (pentapeptide) |
| Half-life | ~30 min (no DAC) / ~6–8 days (DAC) | ~2 h |
| GH release pattern | Pulsatile (no DAC) / Sustained (DAC) | Pulsatile |
| Cortisol / ACTH effect | Minimal | Minimal (key selectivity feature) |
| Prolactin effect | Minimal | Minimal |
| FDA approval | None | None |
| WADA status | Prohibited (S2) | Prohibited (S2) |
Pituitary somatotrophs — the cells that synthesize and secrete GH — have receptor sites for both GHRH and ghrelin. CJC-1295 occupies the GHRH receptor and activates a cAMP/PKA intracellular cascade. Ipamorelin occupies the ghrelin receptor (GHS-R1a) and activates a separate IP₃/Ca²⁺ cascade. Both cascades converge on the same downstream machinery that triggers GH exocytosis.
When both receptors are occupied simultaneously, the two signals amplify each other — producing a GH pulse significantly larger than the sum of each compound alone. This receptor-level synergy, rather than mere additive effect, is why the combination is the most studied GH-axis protocol in the research literature.
Timing matters for the no-DAC form: because CJC-1295 (no DAC) has a half-life of ~30 minutes and ipamorelin ~2 hours, administering them together maximizes the window of simultaneous receptor occupancy.
No DAC (Mod GRF 1-29)
t½ ~30 min · Pulsatile
Studied for
Trade-offs
With DAC
t½ ~6–8 days · Sustained
Studied for
Trade-offs
What is the main difference between CJC-1295 and ipamorelin?
They act on entirely different receptors. CJC-1295 (a GHRH analog) binds the GHRH receptor via a cAMP/PKA cascade. Ipamorelin (a GHRP) binds the ghrelin receptor (GHS-R1a) via an IP₃/Ca²⁺ cascade. Because the two pathways converge downstream on the same pituitary somatotroph, combining them produces synergistically larger GH pulses than either alone.
Why are CJC-1295 and ipamorelin often studied together?
When a GHRH-receptor signal (CJC-1295) and a ghrelin-receptor signal (ipamorelin) arrive at the same pituitary somatotroph simultaneously, the two intracellular cascades amplify each other. The combined GH pulse is substantially larger than additive. This synergy is the primary rationale for studying them as a combination rather than individually.
What is the difference between CJC-1295 with DAC and without DAC?
The DAC (Drug Affinity Complex) addition extends half-life from ~30 minutes (no DAC) to ~6–8 days (DAC) by allowing covalent binding to serum albumin. The no-DAC form produces brief, pulsatile GH pulses compatible with natural GH rhythm. The DAC form produces sustained GH and IGF-1 elevation but blunts pulsatility. The choice between them in research depends on whether pulsatile vs sustained exposure is the endpoint of interest.
What makes ipamorelin selective compared to other GHRPs?
Earlier GHRPs (GHRP-6, hexarelin) release GH alongside ACTH, cortisol, and prolactin — hormones researchers generally prefer not to elevate. Ipamorelin activates GHS-R1a with high selectivity, releasing GH without meaningfully raising the others. This selectivity is the primary reason ipamorelin is the most widely used GHRP in combination research.
Are CJC-1295 and ipamorelin FDA-approved?
No. Neither compound is FDA-approved. Both are prohibited by the World Anti-Doping Agency under category S2 (Peptide Hormones). The only currently approved GH-axis peptide in this catalog is tesamorelin (Egrifta), approved for a specific HIV-related indication.
What is the evidence base for CJC-1295 and ipamorelin?
Both have pharmacological characterization data (receptor binding, GH release curves) and some human pharmacokinetic/pharmacodynamic data. For CJC-1295, peer-reviewed human PK data on GH and IGF-1 effects exists. The evidence base for specific endpoints like body composition is thinner and mostly from small trials or case series. Neither compound has completed Phase 3 clinical trials.
Research reference only. Neither CJC-1295 nor ipamorelin is FDA-approved. Both are WADA-prohibited. Nothing here constitutes medical advice or dosing guidance.